Provided by Tiger Trade Technology Pte. Ltd.

Acumen Pharmaceuticals, Inc.

2.61
-0.2800-9.69%
Post-market: 2.650.0400+1.53%19:49 EDT
Volume:369.34K
Turnover:1.01M
Market Cap:188.48M
PE:-1.59
High:2.95
Open:2.92
Low:2.59
Close:2.89
52wk High:3.60
52wk Low:1.21
Shares:72.21M
Float Shares:37.05M
Volume Ratio:0.97
T/O Rate:1.00%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6370
EPS(LYR):-2.0035
ROE:-120.50%
ROA:-45.77%
PB:3.29
PE(LYR):-1.30

Loading ...

Acumen Pharmaceuticals Q4 EPS $(0.41) Beats $(0.43) Estimate

Benzinga Earnings
·
Mar 26

Acumen Pharma posts smaller-than-expected 2025 loss on lower G&A costs

Reuters
·
Mar 26

Acumen Pharmaceuticals FY2025 EPS Loss Of $2.00 Vs. Loss Of $1.71 YoY, Cash, Cash Equivalents And Marketable Securities Of $116.9M With Cash Runway Into Early 2027

Benzinga Earnings
·
Mar 26

Acumen FY2025 net loss widens 18.57% to $121 million; operating loss climbs 8.62% to $124 million

Reuters
·
Mar 26

BRIEF-Acumen Pharmaceuticals, Inc. FY Income From Operations USD -123.832 Million Vs. IBES Estimate USD -127.9 Million

Reuters
·
Mar 26

Acumen Pharmaceuticals, Inc. FY Operating Expenses USD 123.832 Million

THOMSON REUTERS
·
Mar 26

Acumen Pharmaceuticals, Inc. FY Net Income USD -121.335 Million VS. Ibes Estimate USD -124.8 Million

THOMSON REUTERS
·
Mar 26

Acumen Pharmaceuticals Inc - Expects Topline Results for Altitude-Ad Phase 2 Study in Late 2026

THOMSON REUTERS
·
Mar 26

Acumen Pharmaceuticals Inc - Targets Ind Filing for Lead Ebd Clinical Candidate in Mid-2027

THOMSON REUTERS
·
Mar 26

Acumen Pharmaceuticals, Inc. FY Basic EPS USD -2

THOMSON REUTERS
·
Mar 26

Press Release: Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights

Dow Jones
·
Mar 26

U.S. Earnings Preview: Before Market Open March 26

Dow Jones
·
Mar 26

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 25

Acumen Pharmaceuticals Inc expected to post a loss of 45 cents a share - Earnings Preview

Reuters
·
Mar 24

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 23